Holen Sie sich die Stockscreener-App
17.83
4.36%
-0.74
Novocure Ltd Aktie (NVCR) Neueste Nachrichten
Taking on analysts’ expectations and winning: NovoCure Ltd (NVCR) - SETE News
Chief Financial Officer Cordova Ashley sold 688 shares of NovoCure Ltd [NVCR] - Knox Daily
Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects - Simply Wall St
NovoCure Ltd (NVCR) expanding its growth trajectory ahead - SETE News
Alternating Electric Field Tumor Treatment Market Business - openPR
Financial Health Check: Examining NovoCure Ltd (NVCR)’s Key Ratios - The Dwinnex
NovoCure Ltd (NVCR)’s stock chart: A technical perspective - US Post News
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy - StockTitan
NovoCure Ltd [NASDAQ: NVCR] Sees Increase in Stock Value - Knox Daily
Why NovoCure Stock Dived by 13% This Week - The Motley Fool
NovoCure (NASDAQ:NVCR) Shares Down 5.5% - MarketBeat
NovoCure (NASDAQ:NVCR) Stock Price Up 13.7% - MarketBeat
Stock Surge: NovoCure Ltd (NVCR) Closes at 16.70, Marking a -0.30 Increase/Decrease - The Dwinnex
NVCR November 15th Options Begin Trading - Nasdaq
The Psychology of NovoCure Ltd Inc. (NVCR) Price Performance: Understanding Market Sentiment - The InvestChronicle
NovoCure (NASDAQ:NVCR) Shares Gap Down to $19.44 - MarketBeat
Novocure announces leadership transition, CEO to retire By Investing.com - Investing.com Canada
Novocure falls as CEO Asaf Danziger to step down - XM
There is no way NovoCure Ltd (NVCR) can keep these numbers up - SETE News
Novocure announces leadership transition, CEO to retire - Investing.com
Novocure announces planned CEO transition, COO to step down - TipRanks
Novocure Announces Planned CEO Transition - Financial Times
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Perhaps timely catching NovoCure Ltd (NVCR) would be a good idea - SETE News
Gaining Ground: NovoCure Ltd (NVCR) Closes Higher at 19.75, Up 0.10 - The Dwinnex
NovoCure Ltd (NVCR) Stock: A Year of Decreases and Increases - The InvestChronicle
NVCR’s latest rating updates from top analysts. - Knox Daily
NovoCure (NASDAQ:NVCR) Trading Up 2.8% - MarketBeat
What technical indicators reveal about NVCR stock - US Post News
Novocure to Participate in 2024 Wells Fargo Healthcare Conference - Yahoo Finance
Anaplastic Astrocytoma Market Report Details Trends, and Future Opportunities - WhaTech
AngioDynamics (NASDAQ:ANGO) and NovoCure (NASDAQ:NVCR) Head to Head Review - Defense World
Baillie Gifford & Co. Has $28.91 Million Stock Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Insider Selling: Cordova Ashley, NovoCure Ltd [NVCR] Chief Financial Officer divested 688 shares - Knox Daily
A better buy-in window may exist right now for NovoCure Ltd (NVCR) - SETE News
NovoCure Ltd (NVCR) stock analysis: A simple moving average approach - US Post News
Market Watch: NovoCure Ltd (NVCR)’s Noteworthy Drop, Closing at 17.90 - The Dwinnex
NovoCure (MEX:NVCR) Graham Number : MXNN/A (As of Jun. 2024) - GuruFocus.com
NovoCure (NASDAQ:NVCR) Stock Price Down 3.2% - MarketBeat
NVCR’s 52-Week Rollercoaster: From $10.87 to $31.73 – What’s Next for Investors? - The InvestChronicle
Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet - Yahoo Finance
NVCR (NovoCure) 14-Day RSI : 48.34 (As of Aug. 16, 2024) - GuruFocus.com
NovoCure (NASDAQ:NVCR) Trading Up 9.4% - MarketBeat
NVCR (NovoCure) 9-Day RSI : 31.29 (As of Aug. 15, 2024) - GuruFocus.com
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer - Yahoo Finance
Metric Deep Dive: Understanding NovoCure Ltd (NVCR) Through its Ratios - The Dwinnex
NovoCure Ltd (NVCR)’s stock performance: a year in review - US Post News
Is Spruce Biosciences Inc (NASDAQ: SPRB) A Good Investment Now? - Stocks Register
Metrics That Matter About Ionis Pharmaceuticals Inc (NASDAQ: IONS) - Stocks Register
Things To Consider Before Buying CBRE Group Inc (NYSE: CBRE) - Stocks Register
The Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) Stock Price: Is It Overvalued? - Stocks Register
NovoCure Ltd [NVCR] Records 200-Day SMA of $15.75 - Knox Daily
NovoCure Limited (NASDAQ:NVCR) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
NovoCure (NASDAQ:NVCR shareholders incur further losses as stock declines 17% this week, taking three-year losses to 86% - Simply Wall St
Market Insight: NovoCure Ltd (NVCR)’s Notable Drop, Closing at 19.46 - The Dwinnex
NVCR Stock on the Rise: A Promising Investment - The InvestChronicle
Tidal Investments LLC Purchases Shares of 44,466 NovoCure Limited (NASDAQ:NVCR) - Defense World
Tidal Investments LLC Purchases New Holdings in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
NovoCure Ltd (NVCR)’s stock decline to 20.48 per share - US Post News
NovoCure Limited (NASDAQ:NVCR) CFO Ashley Cordova Sells 688 Shares of Stock - Defense World
Vanguard Group Inc. Has $156.68 Million Stock Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Vanguard Group Inc. Purchases 264,883 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
Price T Rowe Associates Inc. MD Has $37.18 Million Stake in NovoCure Limited (NASDAQ:NVCR) - Defense World
New Strong Buy Stocks for August 1st - MSN
NovoCure Ltd [NVCR] Director makes an insider purchase of 964 shares worth 23033.0. - Knox Daily
Price T Rowe Associates Inc. MD Increases Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Acadian Asset Management LLC Has $49,000 Stock Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure Ltd’s results are impressive - US Post News
Invenomic Capital Management LP Reduces Stock Holdings in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
1.16%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):